Breast (Benign, Carcinoma Breast, Staging, Treatment) MCQs

Surgery · 199 free questions with answers & explanations.

1. A 45-year-old woman presents with a 2 cm hard, irregular, non-tender lump in the upper outer quadrant of the right breast. Fine-needle aspiration cytology shows malignant ductal cells. Sentinel lymph node biopsy is negative. Immunohistochemistry reveals ER+/PR+/HER2-. What is the most appropriate initial systemic therapy?
2. During a modified radical mastectomy, the surgeon divides branches of the axillary dissection plane and the patient subsequently develops winging of the scapula. Which nerve has been injured?
3. A 38-year-old woman notices a firm, mobile, smooth 1.5 cm lump in the left breast that has been present for two years and has not changed in size. Ultrasound confirms a homogeneous solid mass with well-defined margins. The most likely diagnosis is:
4. A 60-year-old postmenopausal woman is found to have T2N1M0 invasive ductal carcinoma of the breast. Which TNM staging corresponds to this finding?
5. A 48-year-old woman with T2N1M0 ER-positive, HER2-negative breast cancer undergoes neoadjuvant chemotherapy. Post-treatment imaging shows a pathological complete response (pCR). Which statement best describes the significance of pCR in this context?
6. A sentinel lymph node biopsy in a patient with clinically node-negative breast cancer reveals 2 sentinel nodes with isolated tumor cells (ITCs, <0.2 mm) detected only on IHC. According to current staging (AJCC 8th edition), the nodal stage is:
7. Which subtype of phyllodes tumor of the breast is characterized by stromal overgrowth, high mitotic rate (>10/10 HPF), and infiltrative margins, conferring the highest risk of distant metastasis?
8. A patient with locally advanced breast cancer has skin edema, erythema, and warmth over the entire breast without a discrete mass, with dermal lymphatic invasion on punch biopsy. This presentation is best classified as:
9. In the Z0011 trial criteria, which patient with a positive sentinel node biopsy may safely avoid axillary lymph node dissection?
10. A 48-year-old woman undergoing sentinel lymph node biopsy for early breast cancer has a positive sentinel node on intraoperative frozen section showing isolated tumour cells (ITC) measuring 0.1 mm. According to current NCCN guidelines, the most appropriate next step regarding axillary management is:
11. Which molecular subtype of breast cancer is characterised by ER-negative, PR-negative, HER2-negative status and is associated with BRCA1 mutations, basal cytokeratin expression, and a predilection for visceral rather than bone metastases?
12. A 35-year-old woman with BRCA2 mutation, no personal cancer history, and a 10-year risk of >25% requests risk-reduction surgery. She opts for bilateral prophylactic mastectomy. The most widely accepted reconstruction technique offering the best cosmetic outcome while preserving skin is:
13. The Oncotype DX® recurrence score (RS) for ER-positive, HER2-negative, node-negative breast cancer stratifies chemotherapy benefit. A patient with RS of 18 (low) is classified as which risk group, and what is the standard treatment recommendation?
14. Paget's disease of the nipple is associated with an underlying breast carcinoma in what proportion of cases, and what is the diagnostic investigation of choice for confirming nipple involvement?
15. A 52-year-old woman undergoes breast conservation surgery for a 2.1 cm ER+/PR+/HER2- grade 2 invasive ductal carcinoma with sentinel node biopsy showing 1 out of 3 nodes positive (micro-metastasis, 0.8 mm). According to the ACOSOG Z0011 trial criteria, the most appropriate next step regarding axillary management is:
16. A 45-year-old woman is found to have a BRCA2 pathogenic variant. Her lifetime risk of breast cancer is estimated at 70%. She elects risk-reducing bilateral mastectomy. Regarding the Oncotype DX Recurrence Score (RS), which statement is MOST accurate regarding its clinical utility?
17. A 38-year-old woman with locally advanced HER2+ breast cancer (T3N2M0) receives neoadjuvant trastuzumab + pertuzumab + docetaxel + carboplatin (TCHP). After surgery, pathological complete response (pCR) is NOT achieved. According to the KATHERINE trial, the most appropriate adjuvant therapy is:
18. A 60-year-old woman is diagnosed with Paget's disease of the nipple. Core biopsy of the retroareolar region shows DCIS with no palpable mass and negative MRI for invasive component. The most appropriate surgical option that preserves breast conservation is:
19. A 42-year-old woman presents with a 3 cm breast lump. Core biopsy confirms a phyllodes tumor with the following histological features: >10 mitoses/10 HPF, marked stromal cellularity, infiltrative margins, and stromal overgrowth. This tumor is classified as:
20. The ACOSOG Z0011 trial changed the management of sentinel lymph node biopsy (SLNB) in breast cancer. Which of the following best describes its key conclusion?
21. A 42-year-old woman with HER2-positive, HR-negative breast cancer (T2N1M0) completes neoadjuvant chemotherapy with trastuzumab. Pathological complete response (pCR) is achieved. Which statement about her further HER2-targeted therapy is most accurate?
22. Regarding the Nottingham Prognostic Index (NPI) for breast cancer, which combination of parameters constitutes its calculation?
23. A woman with BRCA1 mutation undergoes risk-reducing bilateral salpingo-oophorectomy (RRSO). Which additional statement about her breast cancer risk management is most evidence-based?
24. Paget's disease of the nipple is most accurately characterized by which of the following statements?
25. A 52-year-old woman with newly diagnosed invasive ductal carcinoma of the right breast (2 cm, ER+/PR+/HER2−, clinically node-negative) undergoes sentinel lymph node biopsy. Two sentinel nodes contain isolated tumour cells (ITC, <0.2 mm). According to the ACOSOG Z0011 trial criteria, what is the most appropriate next step?
26. Which oncotype DX Recurrence Score (RS) threshold, as established by the TAILORx trial, allows patients with ER+/HER2−, node-negative breast cancer to safely omit adjuvant chemotherapy and receive endocrine therapy alone?
27. A 45-year-old premenopausal woman with BRCA1 mutation has a prophylactic bilateral mastectomy. Histology reveals a 6 mm grade 1 invasive lobular carcinoma in the right breast. The BRCA1 mutation most strongly predisposes to which breast cancer subtype?
28. A 58-year-old woman completes 5 years of tamoxifen for ER+ breast cancer and remains postmenopausal. The MA.17 and ATLAS trials support which subsequent strategy to further reduce late recurrence risk?
29. In the Nottingham Grading System for breast carcinoma, which three histological features are scored from 1–3 each?
30. A 42-year-old woman is diagnosed with ER-positive, HER2-negative, node-negative breast cancer (T1N0M0, grade 2). OncotypeDx recurrence score returns as 18. According to the TAILORx trial findings, what is the recommended adjuvant treatment?
31. Which classification system specifically stratifies breast cancer based on intrinsic molecular subtypes identified by gene expression profiling, including Luminal A, Luminal B, HER2-enriched, and Basal-like?
32. A 55-year-old woman with BRCA2 mutation undergoes risk-reducing bilateral salpingo-oophorectomy. Concurrent risk-reducing mastectomy is being discussed. The lifetime breast cancer risk reduction achieved by bilateral prophylactic mastectomy in BRCA1/2 carriers is approximately:
33. The ACOSOG Z0011 trial changed surgical practice for sentinel node biopsy in breast cancer. Which of the following best summarizes its landmark conclusion?
34. A woman with inflammatory breast cancer shows erythema and peau d'orange involving 2/3 of the breast. She has biopsy-proven dermal lymphatic invasion. According to AJCC staging, this is staged as:
35. The ATAC trial established which of the following in the adjuvant endocrine treatment of post-menopausal hormone receptor-positive early breast cancer?
36. A 42-year-old premenopausal woman with ER+/HER2- pT2N1M0 breast cancer has an Oncotype DX recurrence score of 28. According to the TAILORx trial, what is the recommended adjuvant systemic treatment?
37. In the Z0011 trial, which subset of patients with a positive sentinel lymph node was shown NOT to require axillary lymph node dissection when undergoing breast-conserving surgery with whole-breast radiation?
38. A woman with invasive lobular carcinoma of the breast shows bilateral 'shrinkage' pattern on MRI rather than a single mass. Which molecular characteristic of invasive lobular carcinoma explains its diffuse infiltrative growth pattern?
39. In nipple-sparing mastectomy with immediate implant-based reconstruction, which factor is the STRONGEST contraindication to nipple preservation?
40. A 52-year-old woman with ER+/PR+ HER2- invasive lobular carcinoma (T2N1M0) undergoes neoadjuvant chemotherapy followed by mastectomy. The resected specimen shows no residual invasive disease (pathological complete response). Which biological marker best predicts long-term outcome in this specific molecular subtype after achieving pCR?
41. In the Z0011 trial, sentinel lymph node biopsy (SLNB) showed 1-2 positive sentinel nodes in patients with early breast cancer undergoing breast-conserving surgery (BCS) and whole breast irradiation. Which management was shown to be non-inferior to axillary lymph node dissection (ALND) in this trial?
42. A 45-year-old premenopausal woman with hormone receptor-positive HER2-negative early breast cancer completes 5 years of adjuvant tamoxifen. Genomic profiling reveals a high recurrence score. According to the ATLAS trial findings, what is the recommended extended adjuvant hormonal strategy?
43. A triple-negative breast cancer patient with germline BRCA1 mutation achieves residual disease after neoadjuvant chemotherapy. According to the CREATE-X and OlympiA trials, which adjuvant therapeutic strategy improves disease-free survival most significantly?
44. Which of the following correctly describes the Van Nuys Prognostic Index (VNPI) used in managing ductal carcinoma in situ (DCIS) of the breast?
45. A 52-year-old woman with ER+/PR+/HER2- breast cancer (cT2N1M0) undergoes neoadjuvant chemotherapy with anthracycline-taxane regimen. Post-mastectomy pathology reveals residual disease in 2 sentinel nodes. According to the CREATE-X trial findings, which adjuvant treatment is NOW indicated?
46. A 45-year-old woman with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy is found to have BRCA1 germline mutation. Which agent, added to carboplatin-based neoadjuvant regimen, has shown benefit in the GeparSixto trial for TNBC?
47. A patient undergoes axillary lymph node dissection for breast cancer. She subsequently develops lymphedema. The pathophysiological mechanism of breast cancer-related lymphedema primarily involves:
48. In the TARGIT-A trial comparing intraoperative radiotherapy (IORT) with targeted intrabeam device versus whole-breast external beam radiotherapy (WBRT) in early breast cancer, which finding is correct?
49. A 38-year-old BRCA2 mutation carrier requests risk-reducing bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastectomy (RRM). Which statement accurately reflects current evidence-based counseling?
50. A 48-year-old woman with ER+/PR+/HER2- invasive ductal carcinoma (T2N1M0) undergoes breast-conserving surgery and sentinel lymph node biopsy revealing 2/3 sentinel nodes positive. Axillary node dissection is being considered. Which trial demonstrated non-inferiority of sentinel lymph node biopsy alone (without completion axillary dissection) in patients receiving whole-breast radiotherapy?
51. A 35-year-old BRCA1 mutation carrier with newly diagnosed triple-negative breast cancer (T1cN0M0) desires risk-reducing contralateral mastectomy at the same time as therapeutic mastectomy. The OncotypeDX recurrence score is not relevant here. Which pathological feature of triple-negative breast cancer most strongly correlates with response to neoadjuvant platinum-based chemotherapy?
52. According to the 8th edition AJCC staging for breast cancer, a patient with T2N0M0 disease but a Oncotype DX Recurrence Score of 10 (low) and ER+/HER2- status would be classified as:
53. A 55-year-old postmenopausal woman completed 5 years of adjuvant tamoxifen for ER+ breast cancer. She now presents for discussion of extended adjuvant therapy. The MA.17 trial supports the use of which agent as extended adjuvant therapy beyond 5 years of tamoxifen?
54. A 42-year-old woman presents with a painless discrete lump in the upper outer quadrant. Fine needle aspiration cytology shows C3 (probably benign) result and imaging is BI-RADS 4A. Which statement best describes the appropriate management according to the 'triple assessment' principle?
55. A 48-year-old woman with a T2N1M0 (Stage IIA) ER-positive, HER2-negative invasive ductal carcinoma undergoes neoadjuvant chemotherapy and achieves a pathological complete response (pCR). Which scoring system is used intraoperatively to assess sentinel lymph node status and determines eligibility for axillary lymph node dissection avoidance?
56. In the ACOSOG Z0011 trial, patients with clinically node-negative breast cancer and 1–2 positive sentinel lymph nodes who underwent breast-conserving surgery and whole-breast irradiation were NOT subjected to completion axillary lymph node dissection. The key conclusion was:
57. Which molecular subtype of breast cancer is characterized by high Ki-67, ER-negative, PR-negative, HER2-negative expression, carries the worst prognosis, and benefits most from platinum-based neoadjuvant chemotherapy — particularly in BRCA1-mutated cases?
58. A 35-year-old woman presents with a spontaneous unilateral single-duct bloody nipple discharge. On ductoscopy, a 4mm intraductal lesion is found in the major lactiferous duct. Histopathology shows a papilloma with no atypia. The most appropriate surgical management is:
59. A postmenopausal woman with ER+/PR+ HER2− breast cancer is on adjuvant letrozole (aromatase inhibitor) and develops joint pain and bone loss. Bisphosphonate therapy is initiated. According to current ASCO/St Gallen guidelines, the additional benefit of bisphosphonates (specifically zoledronic acid) in adjuvant breast cancer treatment is:
60. A 52-year-old woman with ER+/PR+ HER2-negative breast cancer, pathological T2N1M0, undergoes breast-conserving surgery with axillary clearance. Her Oncotype DX recurrence score returns at 18. According to TAILORx trial findings, what is the most appropriate adjuvant systemic therapy?
61. A 45-year-old woman with invasive lobular carcinoma of the right breast, T2N0M0, ER+/PR+/HER2-, undergoes sentinel lymph node biopsy which reveals 2 positive sentinel nodes with no extranodal extension. Per the Z0011 trial criteria, what is the recommended axillary management if she proceeds to breast-conserving surgery with whole breast irradiation?
62. A 38-year-old woman with triple-negative breast cancer (T3N2M0) achieves pathological complete response (pCR) after neoadjuvant chemotherapy. She then undergoes mastectomy. According to the CREATE-X trial, what additional adjuvant therapy is indicated if residual disease had been found?
63. In phyllodes tumor of the breast, which histological feature most reliably distinguishes malignant from borderline phyllodes?
64. A 60-year-old woman on letrozole for 3 years for stage II ER+ breast cancer complains of severe arthralgia. What is the most appropriate management step before switching therapy?
65. A 52-year-old woman is undergoing neoadjuvant chemotherapy for locally advanced HER2-positive breast cancer. Pathological complete response (pCR) is confirmed post-mastectomy. According to the KATHERINE trial, which agent should be given as adjuvant therapy?
66. A 45-year-old woman has a 2.8 cm invasive ductal carcinoma with clinically negative axillary nodes. Sentinel lymph node biopsy reveals 2 sentinel nodes with isolated tumor cells (ITC) only (< 0.2 mm). According to current guidelines, what is the most appropriate next step?
67. In the ACOSOG Z0011 trial, which patient population was eligible, and what was the key finding that changed axillary management in breast surgery?
68. Cyclin D1 amplification and loss of p16 (CDKN2A) are found in a hormone receptor-positive breast cancer biopsy. Which CDK4/6 inhibitor combination is standard first-line therapy in metastatic HR+/HER2- disease based on MONARCH 3 or PALOMA-3 trial data?
69. A patient with Paget's disease of the nipple and no underlying mass on mammogram or MRI has a punch biopsy showing large pale Paget cells with prominent nucleoli within the epidermis, immunopositive for CK7 and HER2. What is the most appropriate surgical management?
70. A 42-year-old woman with ER-positive, HER2-negative invasive ductal carcinoma (pT2N1M0) has undergone breast-conserving surgery. Her Oncotype DX Recurrence Score is 22. According to the TAILORx trial findings, which of the following best guides her adjuvant systemic therapy?
71. A 55-year-old postmenopausal woman is found to have a 1.8 cm invasive lobular carcinoma of the breast, ER+/PR+/HER2-. She undergoes wide local excision with sentinel lymph node biopsy; 2 of 4 nodes show isolated tumour cells (ITC) only. According to the current AJCC 8th edition breast cancer staging, what is her pathological N stage?
72. During a nipple-sparing mastectomy for BRCA1 mutation carrier (prophylactic), the surgeon performs frozen section of the retroareolar tissue. Which histological finding would mandate nipple removal?
73. A woman with HER2-positive, hormone receptor-negative breast cancer (cT3N2M0) achieves pathological complete response (pCR) after neoadjuvant trastuzumab plus pertuzumab-based chemotherapy. Which treatment strategy is supported by the KATHERINE trial data for her adjuvant phase?
74. A 48-year-old woman presents with a bloody nipple discharge. Mammography is normal. Ultrasound shows a 4 mm intraductal lesion at 10 o'clock, 3 cm from the nipple. The most appropriate next surgical step after failed cytological diagnosis is:
75. A 52-year-old woman undergoes breast-conserving surgery for a 2.1 cm invasive ductal carcinoma (ER+/PR+, HER2-negative, grade 2, pT2 N1 M0). Oncotype DX recurrence score returns as 18. What is the most appropriate adjuvant systemic therapy?
76. A 38-year-old BRCA1 mutation carrier with a newly diagnosed ER-negative, HER2-negative (triple-negative) breast cancer is planned for neoadjuvant chemotherapy. Which addition to standard anthracycline-taxane regimen has demonstrated improved pathological complete response rates in BRCA-mutated tumors?
77. Sentinel lymph node biopsy (SLNB) in a patient with clinically node-negative breast cancer reveals 2 positive sentinel nodes with macrometastases. She is planned for breast-conserving surgery and whole-breast radiation. According to the Z0011 trial criteria, what is the appropriate axillary management?
78. Phyllodes tumor of the breast: which feature most reliably distinguishes a borderline from a malignant phyllodes tumor on histology?
79. A 45-year-old woman on tamoxifen for 3 years (5-year planned course) is found to be a CYP2D6 poor metabolizer. What is the most clinically significant implication of this pharmacogenomic finding?
80. A 52-year-old woman with ER+/PR+/HER2- invasive ductal carcinoma (T2N1M0, grade 2) undergoes sentinel lymph node biopsy revealing 2 positive nodes with no extranodal extension. The Z0011 trial criteria are met. Which is the most appropriate axillary management?
81. Oncotype DX recurrence score is used primarily to guide chemotherapy decisions in which subtype of breast cancer?
82. A 38-year-old BRCA1 mutation carrier who has completed childbearing requests prophylactic surgery. She has dense breasts on mammography and no evidence of cancer. The most appropriate surgical counselling includes which combination?
83. Phyllodes tumour of the breast is correctly classified into borderline category based on which histological feature?
84. In the neoadjuvant setting for HER2-positive breast cancer, dual HER2 blockade with trastuzumab and pertuzumab is given. The NeoSphere trial showed that pathological complete response (pCR) rates were highest in which group?
85. A 48-year-old woman with newly diagnosed ER+/HER2- breast cancer (T2N1M0) undergoes neoadjuvant chemotherapy. Residual disease is found at surgery. According to the CREATE-X trial, which agent should now be added to her adjuvant regimen?
86. In sentinel lymph node biopsy for breast cancer, which mapping agent combination provides the highest detection rate and lowest false-negative rate compared to either agent alone?
87. A 62-year-old woman with ER+/HER2- node-positive breast cancer completes 5 years of adjuvant aromatase inhibitor therapy. The MA.17R trial supports extension of letrozole to how many total years to reduce late recurrence?
88. In the ACOSOG Z0011 trial, women with T1-2 breast cancers and 1-2 positive sentinel nodes who underwent breast-conserving surgery and whole breast radiation were randomized to axillary lymph node dissection versus no dissection. Which finding was most significant?
89. Which immunohistochemical marker pattern defines a triple-negative breast cancer (TNBC) with basal-like subtype and predicts response to immune checkpoint inhibitors in combination with chemotherapy?
90. A 48-year-old woman is found to have a 2.2 cm invasive ductal carcinoma of the right breast with one axillary lymph node positive on sentinel node biopsy (micrometastasis, 0.3 mm deposit). Pathology shows ER+/PR+, HER2-. According to current AJCC 8th edition staging incorporating biomarkers, the T and N staging is T2 N1mi. What is the pathological prognostic stage group?
91. A 35-year-old BRCA1 mutation carrier requests risk-reduction surgery. She has dense breasts (ACR category D) and her 10-year risk is estimated at 65%. After bilateral risk-reducing mastectomy, what is the approximate risk reduction in breast cancer incidence?
92. A 55-year-old woman has a biopsy-proven invasive lobular carcinoma, 3 cm in size, ER+/PR+, HER2-negative, with an Oncotype DX recurrence score of 18. She has no axillary node involvement. According to the TAILORx trial data, what is the recommended adjuvant systemic therapy?
93. A woman undergoes wide local excision for DCIS. Margins are reported as 1 mm. According to current SSO-ASTRO consensus guidelines, what is the minimum acceptable margin width for DCIS treated with whole breast irradiation?
94. A 52-year-old woman presents with spontaneous bloody nipple discharge from one duct opening. Ultrasound shows a 6 mm intraductal lesion. The most likely diagnosis and recommended surgical procedure are:
95. A 52-year-old woman with invasive ductal carcinoma (T2N1M0) undergoes neoadjuvant chemotherapy. Post-treatment pathology shows no residual invasive carcinoma in the breast or lymph nodes (ypT0ypN0). According to the CREATE-X trial findings, which additional therapy is indicated because she had residual disease at surgery?
96. In breast cancer staging, the AJCC 8th edition introduced a 'Prognostic Stage' that incorporates biologic factors alongside anatomic TNM. Which combination of factors is now used to assign Prognostic Stage Group?
97. A 45-year-old woman undergoes sentinel lymph node biopsy (SLNB) for T1N0 invasive ductal carcinoma. Two sentinel nodes are removed: one contains a 0.4 mm cluster of tumor cells and the other is negative. According to ACOSOG Z0011 trial criteria, what is the recommended management?
98. Phyllodes tumour of the breast is classified as benign, borderline, or malignant. Which histological feature is MOST important in distinguishing borderline from malignant phyllodes tumour?
99. A 38-year-old BRCA1-positive woman elects risk-reducing bilateral salpingo-oophorectomy (RRSO) and bilateral prophylactic mastectomy. Which statement best describes the risk-reduction achieved by prophylactic mastectomy in BRCA1 carriers?
100. OlympiA trial (2021) studied adjuvant olaparib in early breast cancer. In which patient population was adjuvant olaparib shown to improve invasive disease-free survival?
101. A 35-year-old woman presents with bloody nipple discharge from a single duct opening in the left breast. There is no palpable mass and mammogram is normal. The MOST likely diagnosis and the appropriate investigation are:
102. A 45-year-old woman undergoes sentinel lymph node biopsy (SLNB) for a 2.2 cm invasive ductal carcinoma of the right breast. Two sentinel nodes are found to contain isolated tumour cells (ITC, defined as clusters ≤0.2 mm). According to AJCC 8th edition, the nodal stage is:
103. The ABCSG-8/ARNO-95 combined analysis and the MA.17 trial established which of the following extended adjuvant strategies in postmenopausal women with hormone-receptor-positive early breast cancer who have completed 5 years of tamoxifen?
104. Which of the following correctly describes the Z0011 trial criteria under which axillary lymph node dissection (ALND) can be omitted despite 1–2 positive sentinel nodes?
105. Phyllodes tumour of the breast is best classified histologically using the WHO criteria. Which feature is MOST closely linked to the designation 'malignant' rather than 'borderline'?
106. A 38-year-old BRCA1 mutation carrier opts for risk-reducing salpingo-oophorectomy. Which breast cancer subtype is she MOST likely to develop if a breast cancer were to occur?
107. A 52-year-old woman with ER+/PR+/HER2- breast cancer has a Recurrence Score of 28 on OncotypeDx. According to the TAILORx trial findings, what is the recommended treatment strategy?
108. A 45-year-old woman undergoes sentinel lymph node biopsy (SLNB) for clinically node-negative breast cancer. Two sentinel nodes are found positive with micrometastases (each <2mm). She will receive whole-breast radiation and systemic therapy. According to the ACOSOG Z0011 trial criteria, what is the appropriate next step?
109. In breast cancer staging, a patient has a primary tumor measuring 3.5 cm, 5 axillary lymph nodes positive (all <2cm), and no distant metastasis. According to the TNM 8th edition AJCC staging, what is the clinical stage?
110. A 38-year-old woman is found to carry a BRCA1 pathogenic variant. She has no personal history of cancer but has strong family history. She elects for risk-reducing bilateral salpingo-oophorectomy (RRSO). At what age is RRSO typically recommended for BRCA1 carriers?
111. Inflammatory breast cancer (IBC) is characterized by rapid onset of skin erythema and peau d'orange. Which of the following is the most characteristic histopathological finding that distinguishes IBC?
112. A 60-year-old postmenopausal woman with ER+/PR+/HER2- early breast cancer completes 5 years of tamoxifen. She is assessed for extended adjuvant endocrine therapy. The MA.17R trial evaluated what approach?
113. A 30-year-old woman presents with a well-defined, firm, mobile breast lump measuring 2 cm with characteristic ultrasound features of a fibroadenoma. Core biopsy confirms fibroadenoma without atypia. What is the most appropriate management?
114. The ATAC trial (Anastrozole, Tamoxifen, Alone or in Combination) demonstrated that aromatase inhibitor therapy in postmenopausal ER-positive breast cancer patients was superior to tamoxifen in all of the following respects EXCEPT:
115. A 52-year-old postmenopausal woman undergoes wide local excision for a 1.8 cm grade 2 invasive ductal carcinoma. Sentinel lymph node biopsy shows two out of three sentinel nodes positive with micrometastases (deposits 0.2–2 mm). According to ACOSOG Z0011 trial criteria, the most appropriate management is:
116. Oncotype DX recurrence score is used to guide adjuvant chemotherapy decision-making in which specific subgroup of breast cancer patients?
117. Paget's disease of the nipple is characterized histologically by which of the following?
118. A 35-year-old woman is found to have a BRCA2 pathogenic variant. She has completed her family. She elects prophylactic bilateral salpingo-oophorectomy (PBSO). Which of the following is the recommended timing for PBSO in BRCA2 mutation carriers according to current guidelines?
119. The ALMANAC trial established the role of sentinel lymph node biopsy in breast cancer by comparing it to axillary lymph node dissection. Which finding of this trial changed clinical practice most significantly?
120. A 52-year-old woman with ER-positive, HER2-negative, grade 2 invasive ductal carcinoma of the left breast (T2N0M0) undergoes wide local excision. The ATAC trial is most relevant to deciding which of the following adjuvant systemic therapy options?
121. The CALOR (Chemotherapy as Adjuvant for Locally Recurrent) trial investigated chemotherapy in isolated locoregional breast cancer recurrence. Its primary finding was that chemotherapy benefit was confined to which subgroup?
122. A 45-year-old woman with BRCA1 pathogenic variant and biopsy-confirmed lobular carcinoma in situ in the right breast refuses prophylactic mastectomy. Which chemoprevention agent is LEAST effective in BRCA1 mutation carriers with LCIS?
123. According to the 8th edition AJCC staging for breast cancer, a patient with a 3 cm ER+/PR+/HER2− tumour with 4 involved ipsilateral axillary lymph nodes but no distant metastases has a clinical stage of:
124. In Paget's disease of the nipple without a palpable breast mass and with a negative mammogram, the most appropriate next investigation is:
125. A 52-year-old woman is found to have a 2.8 cm IDC of the left breast with 3 of 12 axillary nodes positive, ER+/PR+/HER2−. The Oncotype DX recurrence score returns 18. According to the TAILORx trial results, the recommended adjuvant systemic therapy is:
126. The Paget's disease of the nipple is characterized histologically by large pale cells with prominent nucleoli within the epidermis. Which of the following statements about its management is MOST accurate?
127. A 45-year-old woman undergoes sentinel lymph node biopsy for a 1.8 cm invasive breast cancer. Two sentinel nodes are retrieved; one contains a 0.4 mm micrometastasis and the other is negative. The Z0011 trial criteria are met. What is the standard recommendation?
128. Inflammatory breast cancer (IBC) is clinically characterised by rapid onset of erythema, warmth, and peau d'orange affecting ≥1/3 of the breast skin, often without a discrete mass. The pathological hallmark is:
129. In a patient with locally advanced breast cancer receiving neoadjuvant chemotherapy, complete pathological response (pCR) is most strongly predictive of improved event-free and overall survival in which molecular subtype?
130. A 52-year-old postmenopausal woman with ER-positive, HER2-negative breast cancer (T2N0M0, grade 2) undergoes Oncotype DX testing. The Recurrence Score returns as 18. According to the TAILORx trial results, what is the most appropriate adjuvant systemic treatment?
131. In the AMAROS trial comparing axillary lymph node dissection (ALND) versus axillary radiotherapy after positive sentinel node biopsy in breast cancer, which outcome was superior in the axillary radiotherapy arm?
132. A 45-year-old woman is found to have a BRCA2 pathogenic variant with no current cancer. She opts for risk-reducing bilateral salpingo-oophorectomy (RRSO). By approximately what percentage does RRSO reduce breast cancer risk in BRCA2 carriers when performed before natural menopause?
133. A patient with locally advanced HER2-positive breast cancer receives neoadjuvant trastuzumab and pertuzumab with chemotherapy and achieves a pathological complete response (pCR) at surgery. According to the KATHERINE trial, what is the adjuvant treatment recommendation if pCR is NOT achieved?
134. Phyllodes tumor of the breast with the following features is classified as malignant: stromal overgrowth, >10 mitoses per 10 HPF, marked stromal atypia, and infiltrating margins. What is the recommended surgical margin for malignant phyllodes?
135. The ACOSOG Z0011 trial changed sentinel lymph node biopsy (SLNB) practice. Which of the following most accurately represents its key conclusion?
136. A 48-year-old woman with invasive ductal carcinoma of the breast is found to have a BRCA1 pathogenic variant. She opts for risk-reducing contralateral prophylactic mastectomy alongside therapeutic mastectomy. Which statement about BRCA1-associated breast cancer is most accurate?
137. A post-menopausal woman with hormone receptor-positive, HER2-negative early breast cancer completes 5 years of tamoxifen. The MA.17 trial informs the decision to extend endocrine therapy. What did MA.17 demonstrate?
138. Phyllodes tumour of the breast differs from fibroadenoma in several important aspects. Which feature MOST reliably distinguishes a borderline/malignant phyllodes tumour from a cellular fibroadenoma?
139. A 48-year-old woman with ER-positive, HER2-negative, node-negative breast cancer has an Oncotype DX recurrence score of 18. According to the TAILORx trial findings, which management is most appropriate?
140. A 55-year-old woman undergoes sentinel lymph node biopsy (SLNB) for a 2 cm ER-positive breast carcinoma and has 2 sentinel nodes found positive for metastasis. She is planned for breast-conserving surgery and whole-breast radiotherapy. According to the ACOSOG Z0011 trial criteria, the next step is:
141. A phyllodes tumor of the breast is excised with a 5 mm margin and pathology reveals stromal hypercellularity, >10 mitoses per 10 HPF, and infiltrative border. What is the correct classification and recommended further management?
142. Which molecular subtype of breast cancer is characterized by ER-negative, PR-negative, HER2-negative status, is associated with BRCA1 mutations, and has a basal-like gene expression profile?
143. A 35-year-old woman presents with a 2 cm breast lump; core biopsy shows lobular carcinoma in situ (LCIS). Which of the following best describes the significance of LCIS?
144. A 52-year-old woman undergoes sentinel lymph node biopsy for a 1.8 cm ER-positive, HER2-negative invasive ductal carcinoma. Two sentinel nodes are removed; both show isolated tumour cells (ITCs) only (< 0.2 mm deposits). According to current guidelines (AJNC/ASCO), the nodal stage is:
145. A patient with ER-positive, HER2-negative, node-negative breast cancer has a 21-gene recurrence score (Oncotype DX) of 16. She is 55 years old and postmenopausal. The TAILORX trial result most applicable to her management is:
146. A 40-year-old BRCA1 mutation carrier undergoes risk-reducing bilateral salpingo-oophorectomy. She subsequently opts for prophylactic bilateral mastectomy. The surgical option that offers the lowest residual breast cancer risk while preserving the best cosmetic outcome is:
147. In the pathological complete response (pCR) assessment after neoadjuvant chemotherapy for breast cancer, the ypT0 ypN0 status is MOST prognostically significant in which subtype?
148. Which classification system specifically stratifies phyllodes tumours of the breast into benign, borderline, and malignant based on stromal cellularity, mitotic rate, nuclear pleomorphism, stromal overgrowth, and tumour borders?
149. A 28-year-old woman presents with a firm, well-defined, mobile 3 cm lump in the upper outer quadrant of the left breast. Ultrasound shows a homogeneous hypoechoic lesion with gentle lobulation and no calcifications. FNAC shows phyllodes-like spindle stroma. The feature that most reliably distinguishes a cellular fibroadenoma from a borderline phyllodes tumour on core biopsy is:
150. A 45-year-old woman with newly diagnosed invasive ductal carcinoma of the right breast (cT2N1M0) undergoes sentinel lymph node biopsy which shows 2 of 3 sentinel nodes positive for metastasis. The Z0011 trial criteria are reviewed. According to the ACOSOG Z0011 trial, which of the following is the most appropriate next step?
151. A 38-year-old BRCA2 mutation carrier has a contralateral prophylactic mastectomy after treatment for stage II left breast cancer. Genetic counselling reveals her sister is also BRCA2-positive. Which of the following cancers carries the highest lifetime risk in BRCA2 mutation carriers compared to the general population?
152. An oncoplastic breast surgeon is planning a therapeutic mammoplasty for a 52-year-old woman with a 3 cm upper outer quadrant cancer in a large-breasted patient (cup size F). The planned excision will remove 35% of breast volume. According to oncoplastic surgery principles, what level (volume replacement vs. volume displacement) of oncoplastic procedure best suits this case?
153. A post-menopausal woman with hormone receptor-positive (ER+/PR+, HER2-negative) node-negative breast cancer is considering adjuvant chemotherapy. The Oncotype DX recurrence score returns as 14. What is the most appropriate management?
154. Phyllodes tumour of the breast is classified by the WHO into benign, borderline, and malignant. Which histological feature best distinguishes malignant phyllodes from borderline phyllodes?
155. In the ATAC trial comparing anastrozole versus tamoxifen as adjuvant endocrine therapy in postmenopausal breast cancer, anastrozole demonstrated superiority primarily in which outcome?
156. A 45-year-old woman with a T2N1M0 ER-positive, HER2-negative breast cancer has a 21-gene recurrence score (Oncotype DX) of 18. According to the TAILORx trial findings, the most appropriate adjuvant systemic treatment is:
157. Paget's disease of the nipple is characterised histologically by the presence of large pale cells within the epidermis. These cells most likely originate from:
158. A 38-year-old BRCA1 carrier undergoes risk-reducing bilateral salpingo-oophorectomy. Which statement regarding her subsequent breast cancer risk is most accurate?
159. In the Z0011 trial (ACOSOG Z0011), sentinel lymph node biopsy without axillary lymph node dissection was found non-inferior to full axillary clearance in which specific patient group?
160. Triple negative breast cancer (TNBC) is defined by absent expression of ER, PR, and HER2. According to the CREATE-X trial, what systemic therapy improved disease-free survival in TNBC patients with residual disease after neoadjuvant chemotherapy?
161. The ATAC trial established that, compared to tamoxifen, anastrozole as adjuvant therapy in postmenopausal hormone receptor-positive breast cancer provides which advantage?
162. In the TNM 8th edition staging of breast cancer, a patient has a 2.8 cm invasive ductal carcinoma with metastasis to 4 ipsilateral axillary lymph nodes, none fixed. What is the pathological N stage?
163. The OlympiAD trial demonstrated clinical benefit of olaparib in metastatic breast cancer patients who carry which germline mutation?
164. Phyllodes tumor of the breast is best classified histologically by which combination of features?
165. In the NSABP B-04 trial, long-term follow-up demonstrated which key finding regarding axillary lymph node dissection in clinically node-negative breast cancer?
166. The SOUND trial investigated the oncological safety of omitting sentinel lymph node biopsy (SLNB) in early breast cancer with clinically and ultrasound-negative axilla. Its primary endpoint was:
167. The CLEOPATRA trial established the combination of pertuzumab + trastuzumab + docetaxel as first-line standard for HER2-positive metastatic breast cancer. The primary endpoint demonstrating superiority was:
168. The MINDACT trial (2016) established that in early breast cancer patients with high clinical risk but low genomic risk by 70-gene signature (MammaPrint), what proportion could safely forgo adjuvant chemotherapy?
169. In breast cancer surgery, the term 'oncoplastic resection volume ratio' guides reconstruction choice. Which oncoplastic technique is BEST suited for a lower-inner quadrant tumour requiring >20% breast volume resection in a large-breasted patient?
170. The POSNOC trial is evaluating which specific management question in early breast cancer with 1–2 sentinel lymph node macrometastases?
171. A 48-year-old woman has a 2.2 cm grade 2 invasive ductal carcinoma, ER+/PR+/HER2−, with clear sentinel nodes. Her Oncotype DX recurrence score is 18. According to TAILORx trial data, what is the recommended management?
172. Paget's disease of the nipple is most commonly associated with underlying breast cancer of which histological type?
173. In the ATAC trial comparing anastrozole versus tamoxifen as adjuvant therapy in postmenopausal early breast cancer, which of the following was a key finding that changed clinical practice?
174. A 45-year-old woman undergoes sentinel lymph node biopsy (SLNB) for a 1.8 cm Grade 2 IDC. The sentinel node shows a 0.4 mm isolated tumour cell cluster (ITC). According to current AJCC 8th edition staging, this node status is classified as:
175. The Z0011 trial (ACOSOG) fundamentally changed axillary management in early breast cancer. Which patient scenario best fits the Z0011 eligibility criteria where axillary lymph node dissection can safely be omitted?
176. In HER2-positive breast cancer, pertuzumab is added to trastuzumab and docetaxel in the neoadjuvant setting based primarily on which trial?
177. A patient has Paget's disease of the nipple without an underlying mass on imaging. The correct surgical management is:
178. A 52-year-old woman with locally advanced HER2-positive breast cancer undergoes neoadjuvant chemotherapy followed by surgery. Pathological complete response (pCR) is not achieved. According to the KATHERINE trial, which adjuvant therapy should be offered?
179. A 45-year-old woman is found to have BRCA1 mutation on genetic testing after her sister died of ovarian cancer. She has no personal history of breast cancer. Which statement about risk-reducing mastectomy in BRCA1 carriers is MOST accurate?
180. Regarding the ACOSOG Z0011 trial in early breast cancer, which conclusion is MOST clinically significant?
181. A 38-year-old woman presents with a breast lump. Core biopsy shows lobular carcinoma in situ (LCIS). What is the MOST appropriate management?
182. A 42-year-old woman with HER2-positive, hormone-receptor-negative invasive ductal carcinoma (cT2N1M0) receives neoadjuvant chemotherapy with pertuzumab and trastuzumab. Post-mastectomy pathology shows residual invasive disease (ypT1N1). According to current guidelines (KATHERINE trial data), what adjuvant therapy should be administered?
183. In the ACOSOG Z0011 trial, which subset of breast cancer patients with sentinel node macrometastases was found to NOT require axillary lymph node dissection?
184. A 35-year-old BRCA1 mutation carrier chooses risk-reducing bilateral salpingo-oophorectomy (RRSO) at age 40 and prophylactic mastectomy. Her lifetime breast cancer risk without intervention is approximately 72%. What is the approximate percentage reduction in breast cancer risk achieved by prophylactic mastectomy alone?
185. A 55-year-old woman undergoes wide local excision for a 2.2 cm ER-positive, HER2-negative invasive lobular carcinoma. Final histology reveals lobular carcinoma in situ (LCIS) at the surgical margin. What is the most appropriate management?
186. Which of the following correctly pairs a breast carcinoma histological subtype with its characteristic immunohistochemical or molecular profile?
187. The BIG 1-98 trial evaluated adjuvant endocrine therapy strategies in postmenopausal hormone receptor-positive early breast cancer. Its primary comparison was:
188. Inflammatory breast carcinoma (IBC) is a distinct clinical entity characterised by peau d'orange appearance and is classified as at least T4d (Stage IIIB) by TNM even without a palpable mass. Its pathological hallmark is:
189. A 32-year-old BRCA2 carrier undergoes risk-reducing bilateral mastectomy. She requests nipple-sparing mastectomy (NSM). Which statement about NSM in risk-reduction is most accurate?
190. Paget's disease of the nipple is associated with underlying breast carcinoma in the majority of cases. What is the pathological hallmark of Paget's disease on nipple biopsy?
191. The ATAC trial compared anastrozole monotherapy versus tamoxifen monotherapy as adjuvant endocrine therapy in postmenopausal early breast cancer. The long-term analysis showed anastrozole's primary advantage was:
192. A 42-year-old premenopausal BRCA1-positive woman with newly diagnosed ER-negative/PR-negative/HER2-negative (triple-negative) breast cancer, T2N1M0, is being counselled on risk-reduction options for the contralateral breast. Risk-reducing contralateral mastectomy reduces the risk of contralateral breast cancer by approximately:
193. A 62-year-old woman undergoes mastectomy for a 2 cm ER-positive, HER2-negative, grade 2 breast cancer with 4 out of 15 lymph nodes positive. She is started on adjuvant chemotherapy and endocrine therapy. Pertuzumab (anti-HER2) is considered but found inappropriate. Why?
194. A 50-year-old woman presents with spontaneous single-duct nipple discharge that is blood-stained. Smear cytology is negative for malignancy. What is the most appropriate investigation and management?
195. The OncotypeDX Recurrence Score (RS) is a 21-gene assay used in hormone-receptor-positive, HER2-negative, node-negative breast cancer. Based on the TAILORx trial, in women aged ≥50 with RS 11–25, the recommended treatment is:
196. A 60-year-old postmenopausal woman is diagnosed with ER-positive, HER2-negative, grade 2 invasive ductal carcinoma of 1.8 cm, N0, M0. Oncotype DX recurrence score is 12. What is the MOST appropriate adjuvant treatment?
197. A 50-year-old woman undergoes skin-sparing mastectomy for right breast carcinoma. She opts for immediate implant-based reconstruction. Postoperatively she requires adjuvant radiation therapy. What is the most significant oncoplastic consideration?
198. A 45-year-old woman with clinically node-negative cT2 N0 ER+ HER2- breast cancer undergoes neoadjuvant chemotherapy. Post-NAC, she achieves a complete pathological response (pCR) in the breast. A dual-tracer (blue dye + radioisotope) sentinel lymph node biopsy (SLNB) is performed. Only 1 sentinel node is identified and is negative. Is axillary lymph node dissection (ALND) warranted?
199. A 30-year-old woman is found to have a BRCA2 pathogenic variant. She desires future pregnancy. She has not been diagnosed with breast cancer. At what age should she begin MRI screening of the breast according to NICE/NCCN guidelines?